It depends on the standard you follow. As of September 2026, Regeneron Pharmaceuticals, Inc. (REGN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones Islamic and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.36% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.4% / 30% · Interest income / Revenue 3.55% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.36% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.0% / 33% · Receivables / Mkt Cap (36m) 8.98% / 49% · Interest income / Revenue 3.55% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 2.36% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.0% / 33.33% · Receivables / Mkt Cap (24m) 8.98% / 33.33% · Interest income / Revenue 3.55% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 4.74% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 20.7% / 33.33% · Receivables / Avg Assets (4Q) 15.3% / 33.33% · Interest income / Revenue 3.55% / 5% | Pass |
| FTSE | Debt / Total Assets 4.47% / 33.33% · (Cash+ST Inv) / Total Assets 20.9% / 33.33% · (Cash+Recv) / Total Assets 38.0% / 33.33% · Interest income / Revenue 3.55% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Regeneron Pharmaceuticals, Inc. (REGN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones Islamic and MSCI, and fails FTSE.
Yes. Regeneron Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.55% of each dividend: Regeneron Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a Healthcare company (Biotechnology) with a market capitalization of $98.5B. The Maz Rating grades it against the other companies in its sector.
Regeneron Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $952.40, Regeneron Pharmaceuticals, Inc. trades at 20.3x trailing earnings, 5.8x sales and 2.9x book value, with an EV/EBITDA of 16.1. Over the last twelve months it generated about $16.9B of revenue and $4.9B of net income. It runs a gross margin of 85.8%, an operating margin of 28.8% and a net margin of 28.5%. It shows return on equity of 15.1%, return on invested capital of 10.6% and a free cash flow yield of 3.9%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 3.35. Over the past 52 weeks the share price ranged from $591.52 to $991.73, with a beta of 0.24.
Regeneron Pharmaceuticals, Inc. pays a dividend yielding 0.39%, with 8% of earnings paid out. Its Maz Dividend Score is 4.97 out of 5, ranked against the other dividend payers in its sector (Safety 4.97, Growth 4.77, Yield 1.97, Consistency 3.58).
49 Wall Street analyst ratings cover the stock: 34 Buy and 15 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.